Moderna shares tumble as leaked Phase 3 melanoma vaccine data triggers sell-the-news move
Moderna shares fell sharply in Thursday trading after Phase 3 data tied to its personalized melanoma vaccine, developed with Merck, leaked ahead of schedule. The market reaction came even though the reported clinical readout was positive. According to MSX.COM data, Moderna dropped to an intraday low of $180.80, down about 26.45% from the previous close and roughly 28.95% below its Oct. 21 high of $254.48. The stock later recovered part of the loss and finished at $202.63, down 17.57% on the day. Reuters reported that the Moderna-Merck combination therapy reduced the risk of melanoma recurrence or death by 42%, while cutting the risk of distant metastasis or death by 38%. After the stock had risen more than 500% at one point this year, the market had already priced in high expectations for both efficacy and future commercialization. UBS and other institutions said the decline looked closer to a classic sell-the-news trade, with investors reassessing whether the current clinical progress can justify the valuation gains seen earlier.








